Analytical Data
-
Gene name
PRES
- Application
-
Alternative Names
SLC26A5; DFNB61; Solute Carrier Family 26 Member 5; Deafness,Neurosensory,Autosomal Recessive 61
-
Species
Pig
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
F1SB52
-
Expression Region
Ala524~Ser712
-
Molecular Weight
27kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of PRES (proline-rich enteroprotein) recombinant proteins has gained significant attention due to their potential role in various biological functions and applications in biotechnology. PRES proteins are known to be involved in cellular processes such as cell growth, differentiation, and stress responses. Their proline-rich domains contribute to unique structural and functional properties, making them an interesting subject for research in protein engineering and therapeutic development. Moreover, the ability to produce PRES proteins through recombinant DNA technology opens new avenues for exploring their mechanisms of action and potential uses in medicine, particularly in the development of novel drugs and vaccines. Understanding the structure-function relationship of these proteins can lead to advancements in treating diseases related to immune response, metabolism, and cellular signaling. Researchers are also investigating the potential of PRES proteins as biomarkers for disease detection and progression, highlighting their relevance in clinical diagnostics. Overall, the exploration of PRES recombinant proteins is a promising field that bridges molecular biology, genetics, and applied sciences, paving the way for innovative solutions to address health challenges.
